|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-2-1
|
|
pubmed:abstractText |
To compare efficacy and tolerability of fulvestrant with aromatase inhibitors and tamoxifen that actually represent the standard of care in hormone-sensitive breast cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1879-0461
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
73
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
220-7
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Fulvestrant in the treatment of advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials.
|
|
pubmed:affiliation |
Department of Medical Oncology, University General Hospital of Heraklion, Greece.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Review,
Meta-Analysis
|
